Jump to any asset
849 assets, updated daily
As of September 15, 2026, Crinetics Pharmaceuticals, Inc. (CRNX) trades at $84.95. CleaRank Financial AI rates it Hold with a fair value of $84.95, in line with the current price. Wall Street's consensus target is $85.00 across 9 analysts. RSI at 87 is in overbought territory, and the price is above its 50-day average of $76.81.
Crinetics Pharmaceuticals, Inc. (CRNX)
Crinetics Pharmaceuticals, Inc. NASDAQ
$84.95
0.00 (0.00%)
Latest Price
AI Analyst Consensus
53 / 100
Crinetics Pharmaceuticals, Inc. (CRNX) is currently trading at $84.95, precisely at its median Wall Street price target of $85. The company has demonstrated exceptional revenue growth, soaring by 2336.3% year-over-year, indicating rapid expansion in its biotechnology operations. Despite this impressive top-line performance, the company reports a negative EPS of -5.05, contributing to a high price-to-sales ratio of 213.80. The biotechnology sector, represented by the XLV ETF, shows a median P/E of -16.82 and revenue growth of 8.1%, suggesting CRNX trades at a significant premium on a P/E basis but is experiencing vastly superior revenue expansion. Recent analyst ratings show a shift towards 'Hold' from 'Buy' for CRNX, with 8 out of 9 analysts currently holding this view. This sentiment, coupled with a moderate sell signal from insider transactions totaling $13.1 million in sales against zero purchases, suggests a cautious outlook from both the sell-side and company insiders. The company's balance sheet appears strong with a low debt-to-equity ratio of 0.04, but its profitability metrics, including a negative operating margin of -527.35%, highlight the challenges of scaling a biotechnology business.
CRNX Price Analysis
Market Metrics
Open
$84.95
Day Range
$84.95 to $84.95
Prev Close
$84.95
52-Week Range
$28.73 to $85.01
Market Cap
$9.01B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
On price-to-sales, the yardstick used here in place of P/E, CRNX trades at 213.80x, far above the sector average of 3.70x.
CRNX Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 4 quarters, CRNX beat estimates 3 times. The stock rose 2 times the next day. Price tends to react positively to beats.
CRNX Analysis
Company's Health
3/5
12-Month Analyst Target
+2.50% Upside
Median of 9 analysts (12-month)
$87.07
AI Technical Analysis
At $84.95, Crinetics Pharmaceuticals is trading above its 50-day Simple Moving Average (SMA) of $76.81 and its 200-day SMA of $50.87, indicating a bullish short-to-medium term trend. The Relative Strength Index (RSI) is at 86.96, firmly in overbought territory, suggesting the stock may be due for a pullback. The Moving Average Convergence Divergence (MACD) is positive at 2.06, supporting the current upward momentum. Key support levels are now established around the 50-day SMA at $76.81, while resistance is being tested near the current price. The RSI's overbought condition, coupled with the 'Moderate Sell Signal' from insider transactions, warrants caution despite the bullish trend indicated by moving averages. Investors should monitor for any signs of reversal as the stock approaches potential resistance levels.
ProTips
- Monitor the RSI closely for any signs of a pullback from its current overbought level of 86.96.
- Given the 'Moderate Sell Signal' from insider transactions, investors should exercise caution and consider the implications of $13.1 million in net sales.
- As a biotechnology company, keep abreast of clinical trial results and regulatory approvals, which are critical catalysts for future growth and valuation.
Key Catalysts
Bullish
Strong Revenue Growth Trajectory
Crinetics Pharmaceuticals has reported exceptional revenue growth of 2336.3%, indicating strong market traction and potential for future profitability.
Source: Company FilingsBearish
Insider Selling Activity
Insiders have net sold $13.1 million in stock with no reported purchases, signaling a potential lack of short-term confidence in the current valuation.
Source: Insider TransactionsBearish
Overbought Technical Conditions
The Relative Strength Index (RSI) is at 86.96, indicating the stock is in overbought territory and may be due for a price correction.
Source: Technical AnalysisNeutral
Analyst Downgrades
Several analysts have recently downgraded CRNX from 'Buy' to 'Hold' or 'Neutral', reflecting a shift in sentiment towards caution.
Source: Analyst RatingsMarket Outlook
Crinetics Pharmaceuticals (CRNX) is expected to maintain its current valuation range in the near term, with analysts setting a median price target of $85, which aligns with its current trading price. The company's extraordinary revenue growth of over 2300% suggests significant market adoption or pipeline success, which could drive future earnings. However, the path to profitability remains a key question, with current EPS estimates for the next year at -4.01. The company's strong balance sheet and low debt provide a cushion for continued investment in growth. The outlook hinges on the company's ability to translate its rapid revenue expansion into sustainable profitability. Positive developments in its drug pipeline, successful clinical trial results, or strategic partnerships could act as catalysts for upside. Conversely, continued net losses, failure to meet future earnings expectations, or a broader market rotation away from growth stocks could pressure the stock lower, potentially testing support levels around the 50-day SMA of $76.81.
Key Statistics
| Market Cap | 9.01B |
|---|---|
| P/E Ratio | N/A (Negative EPS) |
| EPS (TTM) | -5.05 |
| Dividend Yield | 0.00% |
| 52 Week High | 85.01 |
| 52 Week Low | 28.73 |
Crinetics Pharmaceuticals (CRNX) exhibits a high price-to-sales ratio of 213.80, significantly above the sector median of 3.7, reflecting its growth-stage biotechnology profile. The company's profit margin is reported at a remarkable 86.02%, though this is juxtaposed with a significantly negative operating margin of -527.35% and a negative EPS of -5.05, indicating substantial operational costs or research and development expenses are outweighing revenue at this stage. The return on equity is a negative -42.45%, consistent with a loss-making enterprise. Compared to the Healthcare sector's median revenue growth of 8.1%, CRNX's 2336.3% growth is exceptional. However, this growth comes at the cost of profitability, as evidenced by the negative EPS and operating margin. The company's debt-to-equity ratio stands at a very low 0.04, suggesting a strong balance sheet with minimal leverage. The current valuation appears stretched based on traditional profitability metrics, but may be justified by its rapid revenue expansion and future growth potential as assessed by analysts.
Earnings & Growth Analysis
Crinetics Pharmaceuticals' most recent reported earnings for the quarter ending June 2026 showed an EPS of -1.14, beating the estimated -1.18 by 3.39% and resulting in a slight positive price change of 0.12%. Prior to this, the company reported an EPS of 0.05 for the quarter ending March 2026, significantly beating estimates of -0.12% with a 141.67% surprise and a 0.65% stock price increase. However, the company has a history of negative EPS, with a reported loss of -1.23 for the quarter ending March 2026 missing estimates by 2.5% and leading to a -13.82% price drop. The overall trend indicates volatile earnings performance with occasional beats on estimates, but persistent net losses.
Key Risks
The primary risk for Crinetics Pharmaceuticals is its current lack of profitability, with a negative EPS of -5.05 and a significantly negative operating margin of -527.35%, which could deter investors seeking immediate returns. Also, the stock is trading in overbought territory according to its RSI of 86.96, suggesting a potential for a near-term price correction. Insider selling, with $13.1 million in net sales versus no purchases, also presents a cautionary signal regarding management's short-term confidence in the stock's valuation.
Technical Indicators
| RSI (14) | 86.96 |
|---|---|
| MACD | 2.06 |
| SMA 50 | 76.81 |
| SMA 200 | 50.87 |
RSI
Overbought
SMA Cross
Bullish
Price vs SMA
Bullish
MACD
Bullish
Golden Cross in effect with the 50-day SMA ($76.81) above the 200-day SMA ($50.87), price action is firmly bullish above key moving averages, RSI at 87.0 indicates overbought conditions; consider caution for immediate entries.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.28
Weak correlation
Nasdaq 100 (QQQ)
+0.22
Weak correlation
Bitcoin (BTC)
+0.21
Weak correlation
Gold (XAU)
+0.01
Weak correlation
Check Custom Correlation
How does any other asset move with CRNX? One year of daily closes, Pearson correlation.
Try
CRNX Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Entry Strategies pick an entry style
Conservative
$84.10
Slight discount to current
Wait for small dip
Aggressive
$84.95
At current price
Enter now if confident
Risk Management
STOP LOSS
$81.07
MAX LOSS
-3.6%
Volatility-Adjusted Stop Loss
Calculated based on RSI (87.0) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$86.62
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$88.31
+5% (Conservative)
+4.0% (Aggressive)
TARGET 3
$90.83
+8% (Conservative)
+6.9% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for CRNX is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 15, 2026.Growth of $10,000
A $10,000 investment in CRNX in July 2018 would be worth about $34,659 today, compared with about $27,224 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in CRNX today could grow to about $29,775 by 2036 in the base case, with a bull case near $225,895 and a bear case around $3,925. Projections are statistical simulations, not guarantees.
CRNX Stock Price Prediction: 2030
CleaRank's simulation projects a price near $131 for CRNX by 2030 in the base case, from $84.95 today (1.5x over 4 years). The downside path ends near $36.49. These are outcomes of a Monte Carlo simulation run on CRNX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $49.92 | $94.74 | $180 |
| 2028 | $42.69 | $106 | $262 |
| 2029 | $38.84 | $118 | $358 |
| 2030 | $36.49 | $131 | $473 |
| 2031 | $34.98 | $147 | $614 |
| 2032 | $34.02 | $163 | $786 |
| 2033 | $33.46 | $182 | $993 |
| 2034 | $33.20 | $203 | $1,246 |
| 2035 | $33.17 | $227 | $1,551 |
| 2036 | $33.34 | $253 | $1,919 |
Method: 10,000 simulated price paths using CRNX's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. CRNX is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
CRNX Insider Trading Analysis
Bought
None
No open-market buys
Sold
$13.1M
23 Transactions
Insiders
13
Active Traders
Avg Transaction
$571.4K
Moderate size
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Mar 20, 2019 | VIVO CAPITAL VIII, L.L.C.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 417.0K | $9.3M |
| Nov 3, 2023 | STRUTHERS RICHARD SCOTT
Chief Executive Officer
|
Sell | 200.0K | $6.1M |
| Jan 22, 2019 | 5AM VENTURES IV, L.P.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 262.2K | $5.7M |
| Jun 21, 2019 | 5AM VENTURES IV, L.P.
Unknown
|
Sell | 250.0K | $5.6M |
| May 8, 2024 | STRUTHERS RICHARD SCOTT
Chief Executive Officer
|
Sell | 107.4K | $5.3M |
| Apr 17, 2020 | VIVO CAPITAL VIII, L.L.C.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 330.6K | $5.1M |
| Apr 7, 2020 | VIVO CAPITAL VIII, L.L.C.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 306.1K | $4.2M |
| Mar 18, 2019 | 5AM VENTURES IV, L.P.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 154.8K | $3.8M |
| Apr 13, 2022 | STRUTHERS RICHARD SCOTT
Chief Executive Officer
|
Sell | 138.6K | $3.7M |
| Apr 8, 2026 | KNIGHT JEFF E
Chief Operating Officer
|
Sell | 85.2K | $3.4M |
Page 1 of 1
Frequently Asked Questions
What is CRNX's current stock price and consensus rating?
Crinetics Pharmaceuticals (CRNX) is currently trading at $84.95. The consensus rating among Wall Street analysts is 'Hold', with a median price target of $85.
Is Crinetics Pharmaceuticals stock a buy right now?
With a 'Hold' consensus rating and the stock trading at its median price target, CRNX is not presenting a clear buy signal. The RSI is overbought at 86.96, and insider selling indicates caution, suggesting investors may want to wait for a more favorable entry point or clearer positive catalysts.
What are the key technical indicators for CRNX stock?
CRNX is trading above its 50-day and 200-day moving averages ($76.81 and $50.87), indicating a bullish trend. However, its RSI is at 86.96, signaling overbought conditions, which could precede a pullback.
How has Crinetics Pharmaceuticals performed in recent earnings reports?
Recent earnings reports show mixed results, with some quarters beating EPS estimates, such as the quarter ending March 2026 (0.48 actual vs 0.44 estimate). However, the company consistently reports net losses, with an EPS of -1.14 for the quarter ending June 2026.
What is the revenue growth for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals has demonstrated exceptional revenue growth, reporting an increase of 2336.3% year-over-year. This rapid expansion is a key driver for the company's valuation despite its current unprofitability.
What are the main risks facing Crinetics Pharmaceuticals?
Key risks include the company's current unprofitability, with negative EPS and operating margins, and the stock trading in overbought technical territory. Significant insider selling also adds a layer of caution.
What is CRNX's stock forecast for 2030?
Based on Monte Carlo simulations, Crinetics Pharmaceuticals' stock forecast for 2030 shows a base case price of $131.43, with a downside projection of $36.49 and an upside projection of $473.48. These are statistical outcomes, not guarantees.